Clinical testing begins for vaccine to treat hepatitis B
Astrivax Therapeutics has begun clinical testing of AVX70371, an experimental vaccine designed to treat hepatitis B. “Starting clinical development with AVX70371 is the first…
Hepatitis
AusperBio raises $50M to advance AHB-137 for chronic hepatitis B
AusperBio raised $50 million to advance the development of chronic hepatitis B treatment AHB-137. The company said the funding will help it launch Phase…
Sobriety restrictions on hepatitis C treatment raise healthcare costs
People with hepatitis C in the U.S. who are insured through state Medicaid programs that require them to be sober to access treatment are…
Imdusiran combos lead to functional cure in some cases of hepatitis B
The investigational treatment imdusiran used as part of combination therapy regimens has led to a functional cure for eight people with chronic hepatitis…
AHB-137 effective for chronic hepatitis B: Phase 2b clinical trial
AHB-137, Ausperbio’s experimental therapy, safely and effectively suppressed the disease-causing hepatitis B virus (HBV) in people with chronic hepatitis B, according to interim…
Vaccination, testing encouraged as part of Hepatitis Awareness Month
Hepatitis Awareness Month is held every May to raise awareness about viral hepatitis, an inflammation of the liver caused by a virus, and help…
Statins reduce risk of liver cancer, death in chronic viral hepatitis
Treatment with certain types of cholesterol-lowering drugs called statins may help reduce the risk of cirrhosis, or irreversible liver scarring, liver cancer, and death in…
Boosting IRF1 protein prevents growth of hepatitis D virus in study
Increasing the levels of a protein called IRF1 helps suppress infection of the hepatitis D virus (HDV) and its growth inside of cells, a new…
American Liver Foundation gears up for advocacy summit
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
FDA grants fast track status to gene-editing therapy for hepatitis B
The U.S. Food and Drug Administration (FDA) has granted fast track status to PBGENE-HBV, Precision Bioscience’s gene-editing therapy candidate for chronic hepatitis B…
